Comparative Pharmacology
Head-to-head clinical analysis: LYSODREN versus XTANDI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LYSODREN versus XTANDI.
LYSODREN vs XTANDI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adrenocorticolytic agent; causes adrenal cortical necrosis and suppresses adrenal steroidogenesis, especially glucocorticoids and mineralocorticoids.
Androgen receptor inhibitor; binds to the androgen receptor, inhibits nuclear translocation, DNA binding, and transcription of androgen-responsive genes.
Oral, initial dose 2-6 g/day divided in 3-4 doses, increase gradually to 8-10 g/day. Maximum dose 18 g/day.
160 mg orally once daily.
None Documented
None Documented
18-159 days; clinical context: during chronic therapy, steady-state may not be reached for 3-6 months.
Enzalutamide: 5.8 days; active metabolite N-desmethyl enzalutamide: 7.8-8.6 days. Steady state achieved after ~28 days.
Primarily renal excretion of metabolites; about 10% as unchanged drug. Biliary/fecal excretion accounts for <5%.
Primarily hepatic metabolism; 77% of dose recovered in feces (as metabolites), 15% in urine (as metabolites); less than 1% excreted unchanged.
Category C
Category C
Antineoplastic
Antineoplastic